Barinthus BiotherapeuticsSTU:2AB 14 EV-to-EBITDA is 0.65 as of Jul. 06, 2026, which is 12% above its 10-year median of 0.58. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review. Among 393 Biotechnology companies, Barinthus Biotherapeutics ranks better than 83.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Barinthus Biotherapeutics's enterprise value is €-26.62 Mil.
Barinthus Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-41.08 Mil. Therefore, Barinthus Biotherapeutics's EV-to-EBITDA for today is 0.65.
The historical rank and industry rank for Barinthus Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
STU:2AB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.74 Med: 0.58 Max: 86.63
Current: 0.62
During the past 7 years, the highest EV-to-EBITDA of Barinthus Biotherapeutics was 86.63. The lowest was -18.74. And the median was 0.58.
STU:2AB's EV-to-EBITDA is ranked better than 83.46% of 393
companies
in the Biotechnology industry
Industry Median: 13.33
vs STU:2AB: 0.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Barinthus Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Barinthus Biotherapeutics's share price for today is €0.52.
Barinthus Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's EV-to-EBITDA falls into.
Barinthus Biotherapeutics's current Enterprise Value is €-26.62 Mil.
Barinthus Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a EV-to-EBITDA of 0.65 as of Jul. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Barinthus Biotherapeutics. This is 12% above median its historical median of 0.58. According to the industry distribution chart, Barinthus Biotherapeutics ranks #65 out of 393 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Barinthus Biotherapeutics' EV-to-EBITDA too high?
Barinthus Biotherapeutics' current EV-to-EBITDA of 0.65 is 12% above median its 10-year median of 0.58. The Biotechnology industry median EV-to-EBITDA is 13.33. Barinthus Biotherapeutics' value of 0.65 is 95.1% below this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #65 out of 393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' EV-to-EBITDA compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #65 out of 393 companies for EV-to-EBITDA. This places Barinthus Biotherapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.33. Barinthus Biotherapeutics' value of 0.65 is 95.1% below this benchmark. While the company's 10-year median is 0.58 vs. the industry median of 13.33, Barinthus Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.33, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current EV-to-EBITDA of 0.65 is 95.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Barinthus Biotherapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current EV-to-EBITDA is 0.65, which is 12% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current EV-to-EBITDA of 0.65. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current EV-to-EBITDA is 0.65, which is 12% above median its 10-year median of 0.58 and 95.1% below the Biotechnology industry median of 13.33. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current EV-to-EBITDA is 0.65 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
EV-to-EBITDA: 0.65 (12% above median its 10-year median of 0.58)
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
Industry Position: 95.1% below the Biotechnology median (#65 of 393)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
